Very late erosion of Amplatzer occluder device resulting in Cardiac tamponade after 15 years
- 74 Downloads
Transcatheter atrial septal defect (ASD) closure is an alternative to surgical closure . Though the immediate procedural risk is lower compared with surgery, atrial tachyarrhythmias, endocarditis and device-associated thrombus formation can occur [2, 3, 4, 5]. A very serious complication is device erosion or cardiac perforation. Potential risk factors are aortic rim deficiency and/or device oversizing causing flaring of the device around the aortic root or exertion of pressure (e.g. to the atrial roof) or undersizing causing protrusion of the left atrial disk into the aortic root [6, 7, 8]. Erosions typically occur early but cases up to 8 years after device implantation have been described . We report a case of erosion causing pericardial tamponade 15 years after device implantation.
We report a case of a 35-year-old woman underwent closure of a large secundum-type ASD. The procedure was performed in 2001 without complications. Unfortunately, intra-procedural images are no...
Compliance with ethical standards
Conflict of interest
Jan-Erik Guelker: none. Ruben Jansen: none. Kolja Sievert none. Horst Sievert: Study honorary, travel expenses, consulting fees from 4tech Cardio, Abbott Vascular, Ablative Solutions, Ancora Heart, Bavaria Medicine Technologie GmbH, Bioventrix, Boston Scientific, Carag, Cardiac Dimensions, Celenova, Cibiem, CGuard, Comed B.V., Contego, CVRx, Edwards, Endologix, Hemoteq, InspireMD, Lifetech, Maquet Getinge Group, Medtronic, Mitralign, Occlutech, pfm Medical, Recor, Renal Guard, Rox Medical, Terumo, Vascular Dynamics, Venus, Veryan. Stefan Bertog: none.
- 3.Moore J, Hegde S, El-Said H, Beekman R 3rd, Benson L, Bergersen L, Holzer R, Jenkins K, Ringel R, Rome J, Vincent R, Martin G, for the ACC IMPACT Steering Committee (2013) Transcatheter device closure of atrial septal defects: a safety review. JACC Cardiovasc Interv 6:433–442CrossRefPubMedGoogle Scholar
- 4.U.S. FDA (2012) FDA Executive Summary Memorandum—May 24, 2012: Circulatory system advisory panel meeting—transcatheter ASD occluders: clinical update and review of events [pdf]. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/ucm300073.htm. Accessed 24 May 2012
- 7.Amin Z, Hijazi ZM, Bass JL, Cheatham JP, Hellenbrand WE, Kleinman CS (2004) Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc Interv 63(4):496–502CrossRefPubMedGoogle Scholar